A new federal enforcement deadline is set to reshape access to some of the country’s most in-demand weight-loss drugs. Starting May 22, the U.S. Food and Drug Administration (FDA) will prohibit most pharmacies and providers from producing or distributing compounded versions of GLP-1 medications semaglutide and tirzepatide, active ingredients in blockbuster drugs including Ozempic, Wegovy, Mounjaro, and Zepbound.